Sarcomatous Transformation of a Medically Treated Lactotroph Pituitary Neuroendocrine Tumor?
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 161, doi. 10.1007/s12022-023-09757-1
- By:
- Publication type:
- Article
Works matching IS 10463976 AND DT 2023 AND VI 34 AND IP 1
Results: 15
1
2
The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 23, doi. 10.1007/s12022-023-09756-2
- By:
- Publication type:
- Article
3
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 79, doi. 10.1007/s12022-023-09755-3
- By:
- Publication type:
- Article
4
Sclerosing Mucoepidermoid Carcinoma with Eosinophilia of the Thyroid and Mucoepidermoid Carcinoma of the Thyroid: What's in a Name?
- Published in:
- 2023
- By:
- Publication type:
- Letter
5
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 1, doi. 10.1007/s12022-023-09753-5
- By:
- Publication type:
- Article
6
High-Grade Non-Anaplastic Thyroid Carcinomas of Follicular Cell Origin: A Review of Poorly Differentiated and High-Grade Differentiated Carcinomas.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 34, doi. 10.1007/s12022-023-09752-6
- By:
- Publication type:
- Article
7
Thyroblastoma—a Primitive Multilineage Thyroid Neoplasm with Somatic DICER1 Alteration.
- Published in:
- 2023
- By:
- Publication type:
- Letter
8
The Thyroid Pathologist Meets Therapeutic Pharmacology.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 48, doi. 10.1007/s12022-023-09749-1
- By:
- Publication type:
- Article
9
The Presence of Typical "BRAFV600E-Like" Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 112, doi. 10.1007/s12022-022-09747-9
- By:
- Publication type:
- Article
10
TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome?
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 129, doi. 10.1007/s12022-022-09746-w
- By:
- Publication type:
- Article
11
Infiltrative Growth Predicts the Risk of Recurrence After Surgery in Well-Differentiated Non-Functioning Pancreatic Neuroendocrine Tumors.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 142, doi. 10.1007/s12022-022-09745-x
- By:
- Publication type:
- Article
12
Menin Loss in Pheochromocytoma of Multiple Endocrine Neoplasia Type 1.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 156, doi. 10.1007/s12022-022-09744-y
- By:
- Publication type:
- Article
13
The Significance of Unsampled Microscopic Thyroid Carcinomas in Multinodular Goiter.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 119, doi. 10.1007/s12022-022-09743-z
- By:
- Publication type:
- Article
14
The Spectrum of Familial Pituitary Neuroendocrine Tumors.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 57, doi. 10.1007/s12022-022-09742-0
- By:
- Publication type:
- Article
15
Primary Thyroid Mucoepidermoid Carcinoma (MEC) Is Clinically, Prognostically, and Molecularly Different from Sclerosing MEC with Eosinophilia: A Multicenter and Integrated Study.
- Published in:
- Endocrine Pathology, 2023, v. 34, n. 1, p. 100, doi. 10.1007/s12022-022-09741-1
- By:
- Publication type:
- Article